INTRODUCTION
• Cervical cancer is the second most common cancer and the second most common cause of death among cancer in Thai women (ASR 24.5 and 12.8 • Epidemiologic and clinical data for model input and calibration were obtained from published literatures and expert opinions
Cost-effectiveness
• A model was used to estimate the total discount cost and effects (ie. QALYs and ICER) accrued over the 100 year time horizon • Sensitivity analyses was conducted to test the effect of excluding HPV 6/11 related benefits and the effect of vaccine price
RESULTS
• Table 1 shows the cumulative cases of HPV 6/11/16/18-related disease and cervical cancer death prevented with two vaccination strategies over 100 years.
• Considering the recommended threshold of 180,000 THB/QALY 2 , both routine and routine plus catch-up programs are cost-effective (Table 2) • When the health effect of HPV6/11-related diseases were excluded, the ICER for routine vaccination and a routine with catch-up vaccination increased by 56.9% and 57.2%, respectively (Table 2 ).
• Cost of vaccine also influenced the result.
• The routine vaccination was projected to prevent an estimated 13,431,010,999 THB of the disease costs associated with HPV 6/11/16/18 in Thailand over 100 years
CONCLUSION
The school-based HPV vaccination program, using the quadrivalent HPV vaccine, is cost-effective, particularly when catch-up vaccination is incorporated. The results support decision-making process to include HPV vaccination into Thailand's National Immunization Program. * ICERs are reported at a time horizon of 100 years ** Base case: 90% coverage rate, vaccine price of 515 THB, administration fee of THB 0, with 6/11 health effects included, discount rate at 3% + This excluded 6/11 related genital warts benefits; 90% coverage rate, vaccine price of 515 THB, administration fee of 0.00 THB per dose ++ 90% coverage rate, administration fee of 0.00 THB per dose, with 6/11 health effects included, discount rate at 3%
